• ̍̍ CSE: BRAX
  • ̍̍ OTC: BRAXF
  • ̍̍ FWB: 4960

Treat Brain-Based Illnesses

October 22, 2021

Braxia Scientific Featured in National News; W5

Braxia Scientific Featured in National News, W5 Canada’s Most-Watched Documentary Series, Providing Access and Promoting Use of Ketamine to Treat Brain-Based Illnesses TORONTO, ONTARIO October 22, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its inclusion in recent national and local news coverage of psychedelics to treat mental disorders. Braxia Scientific CEO Dr. Roger McIntyre will be featured on CTV’s W5, Canada’s most-watched current affairs and documentary program. The episode, entitled “Psychedelic Healing,” will air on Saturday, October 23, 2021, at 7 p.m. Eastern Standard Time (EST). Braxia Scientific and the Canadian Rapid Treatment Center of Excellence (CRTCE), a wholly owned subsidiary, are also highlighted in a recent article by Toronto Life, a monthly...